Deletion 18q21.2q21.32 involving TCF4 in a boy diagnosed by CGH-array.

Eur J Med Genet

Laboratoires de Génétique Médicale, Hôpital Jeanne de Flandre, CHRU de Lille, France.

Published: June 2008

We report on a 12 year-old boy presenting with severe developmental delay, dysmorphic features, limb anomalies, growth retardation, hypoplastic vermis and corpus callosum. Conventional and high-resolution cytogenetic analyses were normal. CGH-array allowed characterisation of a de novo 6.2 Mb 18q21.2q21.32 interstitial deletion involving TCF4, the recently identified gene responsible for Pitt-Hopkins syndrome (PHS). No tachypnoea-apnoea paroxysms were observed. We discuss the dysmorphic features particularly involving the ears, which might be helpful towards PHS and 18q21 deletion diagnosis.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ejmg.2007.12.002DOI Listing

Publication Analysis

Top Keywords

involving tcf4
8
dysmorphic features
8
deletion 18q212q2132
4
18q212q2132 involving
4
tcf4 boy
4
boy diagnosed
4
diagnosed cgh-array
4
cgh-array report
4
report year-old
4
year-old boy
4

Similar Publications

Hepatoblastoma (HBL) and fibrolamellar hepatocellular carcinoma (FLC) are the most common liver malignancies in children and young adults. FLC oncogenesis is associated with the generation of the fusion kinase, DNAJB1-PKAc (J-PKAc). J-PKAc has been found in 90% of FLC patients' tumors but not in other liver cancers.

View Article and Find Full Text PDF

Evaluation of tumorigenesis-related miRNAs in breast cancer in Egyptian women: a retrospective, exploratory analysis.

Sci Rep

November 2024

Department of Microbial Biotechnology, Biotechnology Research Institute, National Research Centre, EL Bohouth St. (Former El Tahrir St.), Dokki, P.O. 12622, Giza, Egypt.

Breast cancer (BC) is a leading cause of global female cancer-related deaths, despite treatment advancements. A growing focus on investigating microRNA-based therapeutics and their role in BC progression. A computational analysis was performed to identify the potential miRNA-mRNA network involved in the BC pathogenesis and assist with the treatment strategy.

View Article and Find Full Text PDF

MGST1 facilitates novel KRAS inhibitor resistance in KRAS-mutated pancreatic ductal adenocarcinoma by inhibiting ferroptosis.

Mol Med

November 2024

Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100021, China.

Background: Pancreatic ductal adenocarcinoma (PDAC) is a highly lethal cancer with a low 5-year survival rate. Treatment options for PDAC patients are limited. Recent studies have shown promising results with MRTX1133, a KRAS inhibitor that demonstrated potent antitumor activity in various types of tumors with KRAS mutation.

View Article and Find Full Text PDF

Triple-negative breast cancer (TNBC) is the most aggressive breast cancer subtype. The tumor microenvironment (TME) plays a major regulatory role in TNBC progression and is highly infiltrated by suppressive immune cells that reduce anti-tumor immune activity. Although regulatory B cells (Bregs) are a key TME component, knowledge of their function in TNBC is limited.

View Article and Find Full Text PDF

Background: The homologous proteins identified as cellular retinoic acid-binding proteins I and II ( and ) belong to a subset of intracellular proteins characterized by their robust affinity for retinoic acid, which plays an indispensable role in the development of hair follicle, including differentiation, proliferation, and apoptosis in keratinocytes. Previous research on Hu sheep hair follicles revealed the specific expression in dermal papilla cells (DPCs), suggesting that has a potential role in regulating the DPC population. Therefore, the main purpose of this study is to expose the performance of the genes in the development and proliferation of DPCs.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!